Posted 2:09 p.m. Tuesday, March 5, 2024
Navitus to Remove Humira® from Formularies Effective June 1
More than ten biosimilars to Humira® were launched in 2023, introducing price competitiveness for one of the most utilized drugs on the market. Taking advantage of this opportunity, Navitus was an early adopter in adding low wholesale acquisition cost (WAC) / low rebate biosimilars to our formulary.
Navitus remains committed to making medications more affordable and continues to support the availability of biosimilars to reduce cost within the pharmacy benefit. However, formulary additions, without more directive action, will not fully capture the savings available through lowest-net-cost formulary management.
